Free tool
FAERS Monitor: Ontralfy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216190 or its brand name (Ontralfy, Tizanidine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,084
Serious
3,950
56% of reports
Hospitalization
1,985
Death reported
419
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue629
- headache589
- nausea518
- pain497
- drug ineffective484
- product dose omission issue462
- somnolence375
- diarrhoea366
- dyspnoea356
- fall342
- arthralgia334
- dizziness334
- off label use307
- covid-19299
- pruritus274
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 43 |
| 2005 | 27 |
| 2006 | 37 |
| 2007 | 3 |
| 2008 | 48 |
| 2009 | 47 |
| 2010 | 35 |
| 2011 | 81 |
| 2012 | 151 |
| 2013 | 67 |
| 2014 | 99 |
| 2015 | 148 |
| 2016 | 221 |
| 2017 | 194 |
| 2018 | 224 |
| 2019 | 294 |
| 2020 | 434 |
| 2021 | 470 |
| 2022 | 862 |
| 2023 | 862 |
| 2024 | 957 |
| 2025 | 1,009 |
| 2026 | 771 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,075 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| somnolenceSignal | 375 | 5.5 | 5.0 | 1,401 |
| covid-19Signal | 299 | 5.1 | 4.5 | 978 |
| product dose omission issueSignal | 462 | 4.7 | 4.3 | 1,346 |
| fallSignal | 342 | 3.1 | 2.8 | 477 |
| headacheSignal | 589 | 2.8 | 2.6 | 695 |
| painSignal | 497 | 2.4 | 2.2 | 418 |
| fatigueSignal | 629 | 2.4 | 2.2 | 531 |
| arthralgiaSignal | 334 | 2.4 | 2.1 | 273 |
| pruritusSignal | 274 | 2.1 | 1.9 | 163 |
| dizziness | 334 | 2.0 | 1.8 | 167 |
| nausea | 518 | 1.9 | 1.8 | 246 |
| dyspnoea | 356 | 1.9 | 1.7 | 147 |
| diarrhoea | 366 | 1.7 | 1.5 | 104 |
| drug ineffective | 484 | 1.1 | 1.0 | 4 |
| off label use | 307 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.